A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Open to people ages 18 years and up

• Stage IV colorectal adenocarcinoma not amenable to curative resection.
• No prior systemic treatment for unresectable or metastatic disease. Participants who received adjuvant or neoadjuvant therapy may enroll if there was no recurrence within 12 months of the end of treatment.
• Measurable disease per RECIST v1.1.
• ECOG performance status of 0 or 1.
• Adequate organ function determined by laboratory results.

• MSI-H/dMMR per historical data in the medical record.
• BRAF V600E mutation per historical data in the medical record.
• Untreated and/or progressing CNS metastases.
• History of other malignancy within 2 years.
• Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for any indication within the last 3 years.
• Active autoimmune disease that has required systemic treatment in the past 2 years.
• Significant concurrent and/or uncontrolled medical condition.
• History of organ transplant, including allogeneic stem cell transplantation.

Other protocol-defined inclusion/exclusion criteria apply.